Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Current state of practice regarding testosterone supplementation therapy in men with prostate cancer.

Kovac JR, Pan MM, Lipshultz LI, Lamb DJ.

Steroids. 2014 Nov;89:27-32. doi: 10.1016/j.steroids.2014.07.004. Epub 2014 Jul 27. Review.

2.

Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSUREā„¢ registry.

Cary KC, Singla N, Cowan JE, Carroll PR, Cooperberg MR.

J Urol. 2014 Apr;191(4):964-70. doi: 10.1016/j.juro.2013.10.098. Epub 2013 Oct 29.

3.

Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.

Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, Rubello D.

Clin Nucl Med. 2013 May;38(5):305-14. doi: 10.1097/RLU.0b013e3182867f3c. Review.

PMID:
23486334
4.

Testosterone therapy in men with prostate cancer: scientific and ethical considerations.

Morgentaler A.

J Urol. 2013 Jan;189(1 Suppl):S26-33. doi: 10.1016/j.juro.2012.11.028. Review.

PMID:
23234627
5.

Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.

Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK.

Cancer. 2011 Jul 1;117(13):2883-91. doi: 10.1002/cncr.25900. Epub 2011 Jan 10.

6.

Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.

Holzbeierlein JM.

Cancer. 2011 Jul 1;117(13):2830-2. doi: 10.1002/cncr.25899. Epub 2011 Jan 24. No abstract available.

7.

Testosterone therapy in men with prostate cancer: scientific and ethical considerations.

Morgentaler A.

J Urol. 2009 Mar;181(3):972-9. doi: 10.1016/j.juro.2008.11.031. Epub 2009 Jan 16. Review.

PMID:
19150547
8.

Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.

Palma D, Pickles T, Tyldesley S; Prostate Cohort Outcomes Initiative.

BJU Int. 2007 Aug;100(2):315-9.

9.

Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma.

Petraki CD, Sfikas CP.

Histol Histopathol. 2007 Jan;22(1):107-18. doi: 10.14670/HH-22.107. Review.

PMID:
17128417
10.

Hypogonadism following prostate-bed radiation therapy for prostate carcinoma.

Daniell HW, Clark JC, Pereira SE, Niazi ZA, Ferguson DW, Dunn SR, Figueroa ML, Stratte PT.

Cancer. 2001 May 15;91(10):1889-95.

PMID:
11346871

Supplemental Content

Loading ...
Support Center